The stock of BioNexus Gene Lab Corp. (BGLC) has gone down by -11.62% for the week, with a -21.27% drop in the past month and a -73.95% drop in the past quarter. The volatility ratio for the week is 11.90%, and the volatility levels for the past 30 days are 24.36% for BGLC. The simple moving average for the last 20 days is -33.23% for BGLC’s stock, with a simple moving average of -90.49% for the last 200 days.
Is It Worth Investing in BioNexus Gene Lab Corp. (NASDAQ: BGLC) Right Now?
The 36-month beta value for BGLC is also noteworthy at 0.71. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
The public float for BGLC is 8.34M, and at present, short sellers hold a 5.32% of that float. The average trading volume of BGLC on September 19, 2023 was 2.84M shares.
BGLC) stock’s latest price update
The stock of BioNexus Gene Lab Corp. (NASDAQ: BGLC) has decreased by -11.63 when compared to last closing price of 0.98.Despite this, the company has seen a loss of -11.62% in its stock price over the last five trading days. InvestorPlace reported 2023-07-21 that BioNexus Gene Lab (NASDAQ: BGLC ) stock is taking off on Friday after the company uplisted its shares to the Nasdaq Capital Market. That saw the company’s shares start trading on the Nasdaq Capital Market yesterday.
BGLC Trading at -73.04% from the 50-Day Moving Average
After a stumble in the market that brought BGLC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.16% of loss for the given period.
Volatility was left at 24.36%, however, over the last 30 days, the volatility rate increased by 11.90%, as shares surge +1.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -83.22% lower at present.
During the last 5 trading sessions, BGLC fell by -11.62%, which changed the moving average for the period of 200-days by -95.95% in comparison to the 20-day moving average, which settled at $1.2978. In addition, BioNexus Gene Lab Corp. saw -92.40% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BGLC
Current profitability levels for the company are sitting at:
- -4.30 for the present operating margin
- +10.68 for the gross margin
The net margin for BioNexus Gene Lab Corp. stands at -3.26. The total capital return value is set at -6.73, while invested capital returns managed to touch -5.11. Equity return is now at value -8.80, with -6.90 for asset returns.
Based on BioNexus Gene Lab Corp. (BGLC), the company’s capital structure generated 0.85 points at debt to equity in total, while total debt to capital is 0.84. Total debt to assets is 0.65, with long-term debt to equity ratio resting at 0.60. Finally, the long-term debt to capital ratio is 0.60.
When we switch over and look at the enterprise to sales, we see a ratio of 1.48, with the company’s debt to enterprise value settled at 0.00. The receivables turnover for the company is 3.49 and the total asset turnover is 1.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.00.
Conclusion
In summary, BioNexus Gene Lab Corp. (BGLC) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
